首页> 外文期刊>Pediatric Pulmonology >Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
【24h】

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.

机译:单一吸入器中的布地奈德/福莫特罗与仅吸入性类固醇的哮喘治疗相比。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study was to evaluate the efficacy (expressed as effect on lung function) and tolerability of Symbicort(R) (budesonide/formoterol in a single inhaler) in children with asthma.This was a double-blind, double-dummy, randomized, parallel-group, multicenter trial. After a 2-4-week run-in period, 286 asthmatic children (177 boys, 109 girls; mean age, 11 years; mean forced expiratory volume in 1 sec (FEV(1)), 75% predicted normal), previously treated with inhaled corticosteroids (average dose 548 &mgr;g/day), were randomized to 12 weeks' treatment with either budesonide/formoterol 80/4.5 &mgr;g, two inhalations twice daily (n = 148), or an equivalent dose of budesonide 100 &mgr;g, two inhalations twice daily (n = 138). Efficacy variables included morning and evening peak expiratory flow (PEF), spirometery, asthma symptoms, and use of rescue medication (beta(2)-agonists). Serial FEV(1) assessments were carried out on a subgroup of children (budesonide/formoterol, n = 41; budesonide, n = 40) at randomization and at week 12.Relative to baseline, morning PEF (primary variable) increased to a significantly greater extent with budesonide/formoterol than with budesonide alone (7.22% predicted normal vs 3.45% predicted normal; P < 0.001). Evening PEF also increased significantly with budesonide/formoterol (6.13% predicted normal vs. 2.73% predicted normal; P < 0.001), as did mean FEV(1) and serial FEV(1) measured over 12 hr (both P < 0.05). Similar improvements in asthma symptoms and rescue medication use were observed in both groups. The two treatment groups were similar in terms of their adverse-event profile and rates of discontinuation.Budesonide/formoterol in a single inhaler provided rapid improvements in PEF and FEV(1) compared to inhaled budesonide alone. These improvements were sustained throughout the study period. Budesonide/formoterol was well-tolerated in children with moderate persistent asthma. Pediatr Pulmonol. 2002; 34:342-350. Copyright 2002 Wiley-Liss, Inc.
机译:这项研究的目的是评估哮喘患儿的Symbicort(R)(布地奈德/福莫特罗在单次吸入器中)的疗效(表示为对肺功能的影响)和耐受性。随机,平行组,多中心试验。经过2-4周的磨合期后,先前接受过治疗的286名哮喘儿童(177名男孩,109名女孩;平均年龄,11岁; 1秒内的平均强迫呼气量(FEV(1)),预计正常值的75%)吸入皮质类固醇(平均剂量548 mg / g /天),随机分配至布地奈德/福莫特罗80 / 4.5 mg,每天两次吸入两次(n = 148),或等效剂量的布地奈德100 mg,治疗12周≥g,每天两次吸入两次(n = 138)。疗效变量包括早晚呼气峰流量(PEF),肺活量测定,哮喘症状和使用急救药物(β(2)激动剂)。在第12周随机分组时,对亚组儿童(布地奈德/福莫特罗,n = 41;布地奈德,n = 40)进行了系列FEV(1)评估。与单独使用布地奈德相比,布地奈德/福莫特罗的使用范围更大(7.22%预测正常vs. 3.45%预测正常; P <0.001)。布地奈德/福莫特罗的夜间PEF也显着增加(预测正常的为6.13%,预测正常的为2.73%; P <0.001),在12小时内测得的FEV(1)和系列FEV(1)也均如此(均P <0.05)。两组均观察到哮喘症状和急救药物的使用有相似的改善。这两个治疗组的不良事件特征和停药率相似。与单独吸入布地奈德相比,单一吸入器中的布地奈德/福莫特罗可快速改善PEF和FEV(1)。这些改进在整个研究期间一直持续。布地奈德/福莫特罗在中度持续性哮喘患儿中耐受良好。小儿科薄荷油。 2002年; 34:342-350。版权所有2002 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号